152537-01-4

Basic information

• Product Name: 2-(1-BENZHYDRYLAZETIDIN-3-YL)ETHANOL
• Synonyms: 2-(1-BENZHYDRYLAZETIDIN-3-YL)ETHANOL;1-(diphenylmethyl)-3-Azetidineethanol
• CAS NO: 152537-01-4
• Molecular Formula: C₁₈H₂₁NO
• Molecular Weight: 267.37
• Mol File: 152537-01-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 381.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.117±0.06 g/cm3(Predicted)
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: 2-(1-BENZHYDRYLAZETIDIN-3-YL)ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-BENZHYDRYLAZETIDIN-3-YL)ETHANOL(152537-01-4)
• EPA Substance Registry System: 2-(1-BENZHYDRYLAZETIDIN-3-YL)ETHANOL(152537-01-4)

Safety Data

• Hazardous Substances Data: 152537-01-4(Hazardous Substances Data)

Usage

Azetidine derivative

A compound derived from azetidine, a three-membered heterocyclic ring structure.

Benzhydryl group

A benzene ring connected to another benzene ring through two substituents (usually carbon atoms) at the 1,1' positions.

Ethanol group

An alcohol group with two carbon atoms (-CH2-CH3).

Pharmaceutical applications

The potential use of the compound in the development of drugs and medications.

Structural similarity to drugs

The compound has a similar structure to certain drugs, which may indicate its ability to interact with biological systems in a similar way.

Interaction with biological systems

The ability of the compound to bind to and affect the function of biological molecules, such as proteins and enzymes.

Research and drug development

The use of the compound in scientific studies to explore its effects on biological processes and potential therapeutic uses.

Further studies needed

Additional research is required to fully understand the properties and potential applications of the compound.

Upstream product

• 158602-32-5 ethyl 2-[1-(diphenylmethyl)azetidin-3-ylidene]acetate 

Downstream Products

• 942307-65-5 1-Benzhydryl-3-(2-methoxyethyl)azetidine 

Relevant articles and documents

VLA-4 INHIBITORY DRUG

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C-R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

QUINAZOLINE-2, 4-DIONES AS ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of